IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Binimetinib, a MEK Inhibitor

News
2020
2019
Archive

June 25, 2020

Pear Therapeutics and RemedyOne Announce Pharmacy Benefit Manager Coverage for Prescription Digital Therapeutics reSET® and reSET-O® for People with Substance and Opioid Use Disorders
June 18, 2020

Pear Therapeutics Announces Market Authorization of reSET® From the Health Science Authority in Singapore for the Treatment of Adults with Substance Use Disorder
June 17, 2020

Sirnaomics and Precision NanoSystems Have Formed a Partnership
June 17, 2020

IDEAYA and GSK Announce a Broad Partnership in Synthetic Lethality, an Emerging Field in Precision Medicine Oncology
June 17, 2020

Impel Neuropharma Presents Data From INP104 Clinical Program in Acute Migraine at the 2020 American Headache Society (AHS) Virtual Annual Scientific Meeting
June 12, 2020

Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 (Eprenetapopt) and Azacitidine in Patients with TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia at the 25th European Hematology Association Annual Meeting
June 11, 2020

IDEAYA Biosciences Selected to Join Russell 3000® Index
June 10, 2020

Impel NeuroPharma Announces Primary Objectives Met in Pivotal Phase 3 Registration Study of INP104 for the Treatment of Acute Migraine
June 10, 2020

IDEAYA Announces Nomination of Development Candidate, IDE397, for MAT2A Synthetic Lethality Program Targeting MTAP-Deletion Patient Population
June 3, 2020

NodThera Announces Close of $55 Million Series B Financing